Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 15/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.64 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.64 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6120463 | 0.87 | PTGS2 (0.56) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL17878838 | 0.85 | PTGS2 (0.71) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL4027051 | 0.84 | PTGS2 (0.66) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL13430673 | 0.83 | PTGS2 (0.58) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL13114284 | 0.83 | PTGS2 (0.67) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL5551731 | 0.83 | PTGS2 (0.67) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL14422875 | 0.83 | PTGS2 (0.67) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL25150436 | 0.81 | PTGS2 (0.64) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL16093186 | 0.81 | PTGS2 (0.64) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL14429592 | 0.80 | PTGS2 (0.63) | PTGS2PTGS1ABCC4ABCB11PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841457-B2 | Process for cyclooxygenase-2 selective inhibitor | VIRDEV INTERMEDIATES PVT. LTD. (IN) | 2014-09-23 | — | — | US | claimed |
| EP-2649049-A2 | PRODUCE TO PRODUCE ETORICOXIB | Virdev Intermediates Pvt. Ltd. (IN) | 2013-10-16 | — | — | EP | claimed |
| US-20130245272-A1 | PROCESS FOR CYCLOOXYGENASE-2 SELECTIVE INHIBITOR | VIRDEV INTERMEDIATES PVT. LTD. (IN) | 2013-09-19 | — | — | US | claimed |
| WO-2012066570-A2 | A PROCESS FOR CYCLOOXYGENASE-2 SELECTIVE INHIBITOR | VIRDEV INTERMEDIATES PVT. LTD. (IN) | 2012-05-24 | — | — | WO | claimed |
| EP-2551265-B2 | Novel process for the preparation of 1-(6-methylpyridin-3-yl)-2-[4-(methylsulfonyl)phenyl]ethanone, an intermediate of etoricoxib. | F I S - FABBRICA ITALIANA SINTETICI S P A (IT) | 2017-09-13 | — | — | EP | disclosed |
| EP-2649049-B1 | PROCESS TO PRODUCE ETORICOXIB | VIRDEV INTERMEDIATES PVT LTD (IN) | 2016-08-24 | — | — | EP | disclosed |
| EP-2802564-B1 | PROCESS FOR THE SYNTHESIS OF ETORICOXIB | TIEFENBACHER ALFRED E GMBH & CO KG (DE) | 2016-08-10 | — | — | EP | disclosed |
| EP-2802564-B1 | PROCESS FOR THE SYNTHESIS OF ETORICOXIB | TIEFENBACHER ALFRED E GMBH & CO KG (DE) | 2016-08-10 | — | — | EP | disclosed |
| US-9024030-B2 | Process for the synthesis of etoricoxib | ALFRED E. TIEFENBACHER (GMBH & CO. KG) (DE) | 2015-05-05 | — | — | US | disclosed |
| US-9024030-B2 | Process for the synthesis of etoricoxib | ALFRED E. TIEFENBACHER (GMBH & CO. KG) (DE) | 2015-05-05 | — | — | US | disclosed |
| US-9024030-B2 | Process for the synthesis of etoricoxib | ALFRED E. TIEFENBACHER (GMBH & CO. KG) (DE) | 2015-05-05 | — | — | US | disclosed |
| US-20150011771-A1 | PROCESS FOR THE SYNTHESIS OF ETORICOXIB | SHANGHAI GOLDEN PHARMATECH CO., LTD. (CN) | 2015-01-08 | — | — | US | disclosed |
| WO-2013104546-A1 | PROCESS FOR THE SYNTHESIS OF ETORICOXIB | ALFRED E. TIEFENBACHER (GMBH & CO. KG) (DE) | 2013-07-18 | — | — | WO | disclosed |
| WO-2013104546-A1 | PROCESS FOR THE SYNTHESIS OF ETORICOXIB | ALFRED E. TIEFENBACHER (GMBH & CO. KG) (DE) | 2013-07-18 | — | — | WO | disclosed |
| WO-2012066570-A2 | A PROCESS FOR CYCLOOXYGENASE-2 SELECTIVE INHIBITOR | VIRDEV INTERMEDIATES PVT. LTD. (IN) | 2012-05-24 | — | — | WO | disclosed |
| US-20080138282-A1 | imaging agents for the cyclooxygenase (COX-2) enzyme using positronemission tomograpy (PET); C11 or F18 radioisotopes; inflammatory, cancer, diabetes, neurodegenerative diseases | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080138282-A1 | imaging agents for the cyclooxygenase (COX-2) enzyme using positronemission tomograpy (PET); C11 or F18 radioisotopes; inflammatory, cancer, diabetes, neurodegenerative diseases | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-06-12 | — | — | US | disclosed |
| US-20060229338-A1 | 2,3'-bipyridines derivatives as selective cox-2 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-10-12 | — | — | US | disclosed |
| EP-1592666-A1 | 2,3 -BIPYRIDINES DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | Almirall Prodesfarma, S.A. (ES) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004072037-A1 | 2,3'-BIPYRIDINES DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | ALMIRALL PRODESFARMA S.A. (ES) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245272-A1 | PROCESS FOR CYCLOOXYGENASE-2 SELECTIVE INHIBITOR | PTGS2, PTGIS, PTGES2 | PTGS2 1/4885PTGS1 4/4885ABCC4 2658/4885 |
| US-20080138282-A1 | imaging agents for the cyclooxygenase (COX-2) enzyme using positronemission tomograpy (PET); C11 or F18 radioisotopes; inflammatory, cancer, diabetes, neurodegenerative diseases | PTGES2, PTGES, PTGS2 | PTGS2 3/4885PTGS1 5/4885ABCC4 1537/4885 |
| US-20150011771-A1 | PROCESS FOR THE SYNTHESIS OF ETORICOXIB | PTGS1, PTGS2, PTGES2 | PTGS2 2/4885PTGS1 1/4885ABCC4 3866/4885 |
| US-20060229338-A1 | 2,3'-bipyridines derivatives as selective cox-2 inhibitors | PTGS2, PTGES2, PTGER2 | PTGS2 1/4885PTGS1 4/4885ABCC4 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.